These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

420 related articles for article (PubMed ID: 20117337)

  • 1. Defensin-immunology in inflammatory bowel disease.
    Wehkamp J; Stange EF; Fellermann K
    Gastroenterol Clin Biol; 2009 Jun; 33 Suppl 3():S137-44. PubMed ID: 20117337
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Host-microbe interaction: mechanisms of defensin deficiency in Crohn's disease.
    Wang G; Stange EF; Wehkamp J
    Expert Rev Anti Infect Ther; 2007 Dec; 5(6):1049-57. PubMed ID: 18039087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A new look at Crohn's disease: breakdown of the mucosal antibacterial defense.
    Wehkamp J; Stange EF
    Ann N Y Acad Sci; 2006 Aug; 1072():321-31. PubMed ID: 17057212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Defensin deficiency, intestinal microbes, and the clinical phenotypes of Crohn's disease.
    Wehkamp J; Schmid M; Fellermann K; Stange EF
    J Leukoc Biol; 2005 Apr; 77(4):460-5. PubMed ID: 15618294
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced alpha-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn's disease.
    Simms LA; Doecke JD; Walsh MD; Huang N; Fowler EV; Radford-Smith GL
    Gut; 2008 Jul; 57(7):903-10. PubMed ID: 18305068
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Defensins and other antimicrobial peptides in inflammatory bowel disease.
    Wehkamp J; Schmid M; Stange EF
    Curr Opin Gastroenterol; 2007 Jul; 23(4):370-8. PubMed ID: 17545771
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Defensins and inflammation: the role of defensins in inflammatory bowel disease.
    Ramasundara M; Leach ST; Lemberg DA; Day AS
    J Gastroenterol Hepatol; 2009 Feb; 24(2):202-8. PubMed ID: 19215333
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Barrier dysfunction due to distinct defensin deficiencies in small intestinal and colonic Crohn's disease.
    Wehkamp J; Koslowski M; Wang G; Stange EF
    Mucosal Immunol; 2008 Nov; 1 Suppl 1():S67-74. PubMed ID: 19079235
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NOD2 (CARD15) mutations in Crohn's disease are associated with diminished mucosal alpha-defensin expression.
    Wehkamp J; Harder J; Weichenthal M; Schwab M; Schäffeler E; Schlee M; Herrlinger KR; Stallmach A; Noack F; Fritz P; Schröder JM; Bevins CL; Fellermann K; Stange EF
    Gut; 2004 Nov; 53(11):1658-64. PubMed ID: 15479689
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Paneth cell defensins: key effector molecules of innate immunity.
    Bevins CL
    Biochem Soc Trans; 2006 Apr; 34(Pt 2):263-6. PubMed ID: 16545089
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Paneth cells and the innate immune response.
    Wehkamp J; Stange EF
    Curr Opin Gastroenterol; 2006 Nov; 22(6):644-50. PubMed ID: 17053443
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NOD2 and defensins: translating innate to adaptive immunity in Crohn's disease.
    Peyrin-Biroulet L; Chamaillard M
    J Endotoxin Res; 2007; 13(3):135-9. PubMed ID: 17621555
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular and molecular mechanisms underlying NOD2 risk-associated polymorphisms in Crohn's disease.
    Strober W; Asano N; Fuss I; Kitani A; Watanabe T
    Immunol Rev; 2014 Jul; 260(1):249-60. PubMed ID: 24942694
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Events at the host-microbial interface of the gastrointestinal tract. V. Paneth cell alpha-defensins in intestinal host defense.
    Bevins CL
    Am J Physiol Gastrointest Liver Physiol; 2005 Aug; 289(2):G173-6. PubMed ID: 16014978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Paneth cell alpha-defensin deficiency of ileal Crohn's disease is linked to Wnt/Tcf-4.
    Wehkamp J; Wang G; Kübler I; Nuding S; Gregorieff A; Schnabel A; Kays RJ; Fellermann K; Burk O; Schwab M; Clevers H; Bevins CL; Stange EF
    J Immunol; 2007 Sep; 179(5):3109-18. PubMed ID: 17709525
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The role of defensins in the pathogenesis of chronic-inflammatory bowel disease].
    Schmid M; Fellermann K; Wehkamp J; Herrlinger K; Stange EF
    Z Gastroenterol; 2004 Apr; 42(4):333-8. PubMed ID: 15095125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanisms of disease: defensins in gastrointestinal diseases.
    Wehkamp J; Fellermann K; Herrlinger KR; Bevins CL; Stange EF
    Nat Clin Pract Gastroenterol Hepatol; 2005 Sep; 2(9):406-15. PubMed ID: 16265431
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paneth cells, defensins, and the commensal microbiota: a hypothesis on intimate interplay at the intestinal mucosa.
    Salzman NH; Underwood MA; Bevins CL
    Semin Immunol; 2007 Apr; 19(2):70-83. PubMed ID: 17485224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NOD2 mutations and Crohn's disease: are Paneth cells and their antimicrobial peptides the link?
    Grimm MC; Pavli P
    Gut; 2004 Nov; 53(11):1558-60. PubMed ID: 15479670
    [No Abstract]   [Full Text] [Related]  

  • 20. Inflammatory bowel disease: an impaired barrier disease.
    Jäger S; Stange EF; Wehkamp J
    Langenbecks Arch Surg; 2013 Jan; 398(1):1-12. PubMed ID: 23160753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.